Abstract
A Class 1 indication for patients with acute coronary syndrome (ACS) is dual antiplatelet inhibitors therapy (DAPT) including aspirin and a P2Y12 inhibitor. Randomized controlled trials (RCTs) have shown prasugrel and ticagrelor are superior to clopidogrel, but no RCT has directly compared these
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
